Cytori Therapeutics Inc (CYTX) Stock Price, Quote, News and Overview
NASDAQ:CYTX - Nasdaq -
CYTX Quote, Performance and Key Statistics
0.2077
-0.01 (-5.59%)
The current stock price of CYTX is 0.2077 null. In the past month the price decreased by -18.55%. In the past year, price decreased by -69.9%.
About CYTX
Company Profile
Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Company Info
Cytori Therapeutics Inc
3020 CALLAN ROAD
SAN DIEGO CA 92121
CEO: Marc. H. Hedrick
Phone: 858-458-0900
Cytori Therapeutics Inc / CYTX FAQ
What is the stock price of Cytori Therapeutics Inc today?
The current stock price of CYTX is 0.2077 null. The price decreased by -5.59% in the last trading session.
What is the ticker symbol for Cytori Therapeutics Inc stock?
The exchange symbol of Cytori Therapeutics Inc is CYTX and it is listed on the Nasdaq exchange.
On which exchange is CYTX stock listed?
CYTX stock is listed on the Nasdaq exchange.
What is Cytori Therapeutics Inc worth?
Cytori Therapeutics Inc (CYTX) has a market capitalization of 4.60M null. This makes CYTX a Nano Cap stock.
What are the support and resistance levels for Cytori Therapeutics Inc (CYTX) stock?
Cytori Therapeutics Inc (CYTX) has a resistance level at 0.23. Check the full technical report for a detailed analysis of CYTX support and resistance levels.
Should I buy Cytori Therapeutics Inc (CYTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYTX, evaluating the profitability, health, valuation and growth aspects
- Cytori Therapeutics Inc (CYTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Cytori Therapeutics Inc (CYTX) Sales and EPS estimates to see what analysts future expectations are.
- Cytori Therapeutics Inc (CYTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Cytori Therapeutics Inc (CYTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- Cytori Therapeutics Inc (CYTX) Stock Chart to make your own analysis
- Cytori Therapeutics Inc (CYTX) Latest news and press-releases to stay up to date.
Does Cytori Therapeutics Inc (CYTX) stock pay dividends?
CYTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of Cytori Therapeutics Inc (CYTX)?
Cytori Therapeutics Inc (CYTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).
CYTX Technical Analysis
CYTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYTX. CYTX may be in some trouble as it scores bad on both profitability and health.
CYTX Financial Highlights
Over the last trailing twelve months CYTX reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS increased by 29.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -312.24% | ||
| ROA | -46.21% | ||
| ROE | -294.92% | ||
| Debt/Equity | 0.39 |
CYTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 60% to CYTX. The Buy consensus is the average rating of analysts ratings from 1 analysts.